{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/heart-failure-chronic/prescribing-information/managing-ace-inhibitors/","result":{"pageContext":{"chapter":{"id":"06c9d276-e5ea-5a0b-9ff4-343f10034763","slug":"managing-ace-inhibitors","fullItemName":"Managing ACE-inhibitors","depth":2,"htmlHeader":"<!-- begin field d0abf5e5-2474-457c-acf1-55797769eefa --><h2>Managing angiotensin-converting enzyme inhibitors</h2><!-- end field d0abf5e5-2474-457c-acf1-55797769eefa -->","summary":"","htmlStringContent":"<!-- begin item 79cae013-d3d5-411e-ae59-53b288770c2f --><!-- end item 79cae013-d3d5-411e-ae59-53b288770c2f -->","topic":{"id":"3a35207f-30ea-5eca-bfcf-dff091a73359","topicId":"fdc42e20-2c4b-45ed-9093-6c2d4bde6e4d","topicName":"Heart failure - chronic","slug":"heart-failure-chronic","lastRevised":"Last revised in January 2017","chapters":[{"id":"77c928c1-46d0-58c1-ba79-6015f89bc48a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"f0aa9151-9d10-566e-85ec-6ccefed25f20","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"c036596d-f29d-5486-822a-b46af76451d7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"fd5e8a95-3e97-5ec2-98ae-5a10c2373213","slug":"changes","fullItemName":"Changes"},{"id":"4c4375f1-a348-5b99-b895-f04a15c64791","slug":"update","fullItemName":"Update"}]},{"id":"7472c037-35d4-5fd2-bba6-dfd891ade816","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"cde936d1-3945-5bc6-8c22-9106d78cf77c","slug":"goals","fullItemName":"Goals"},{"id":"bfa0b8d3-fac0-500e-a762-f719dc619f1b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5d2cf55e-1ae2-5000-9c94-e9c86d26a824","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c8203a8a-fc22-5378-b33b-34ddf818dea5","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"4b5e4f72-1a3e-531c-be82-a1919603c934","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c206f1b2-7616-587d-b3bf-b65ba5b5adb4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ab1d2b81-1f2b-55e5-abf0-c14e4ae4a78d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"cb83ac3c-e97e-5cab-acca-5abebc7bd6b1","slug":"definition","fullItemName":"Definition"},{"id":"66c995b7-504c-5510-9e77-1a9b27ee7dca","slug":"causes","fullItemName":"Causes"},{"id":"88dbdf7b-53b7-5952-97b9-2312c0a2ce63","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a0b16521-d808-5dfd-89dc-64fc6ae7f6ce","slug":"prognosis","fullItemName":"Prognosis"},{"id":"262fb896-526d-594f-8142-98c291781249","slug":"complications","fullItemName":"Complications"}]},{"id":"72804751-fb0c-5a96-85b5-982feb950f16","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8b798e41-3fbe-5027-9365-da41e1c98e93","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"e6498250-f313-5ea2-a1e8-2d0342823c39","slug":"how-to-manage-suspected","fullItemName":"How to manage suspected"},{"id":"74e553b4-7cb8-52a6-a573-8715f63a2ba8","slug":"how-to-assess","fullItemName":"How to assess"},{"id":"53bf7ae0-a1d0-5fae-9d3b-57cbc6f03bb8","slug":"what-else-could-it-be","fullItemName":"What else could it be"}]},{"id":"38c5edc8-6b4a-5e71-bb70-cf0a09389ae0","fullItemName":"Management","slug":"management","subChapters":[{"id":"97a0eca4-a290-588b-a16a-bc95b93cd893","slug":"confirmed-heart-failure-with-reduced-ejection-fraction","fullItemName":"Scenario: Confirmed heart failure with reduced ejection fraction"},{"id":"34ff8094-815a-55b7-9edd-49f3ac636471","slug":"confirmed-heart-failure-with-preserved-ejection-fraction","fullItemName":"Scenario: Confirmed heart failure with preserved ejection fraction"},{"id":"28fde475-ef24-59d3-9171-a8d59a3fb149","slug":"end-stage-heart-failure","fullItemName":"Scenario: End-stage heart failure"},{"id":"c587255a-a47e-57a1-bc4d-967753c38d11","slug":"information-advice-follow-up-referral","fullItemName":"Scenario: Information and advice, follow-up, and referral"}]},{"id":"e82d6013-cb43-59d5-9e2e-0af05276fb9d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8fd96acc-3fa6-528b-9351-49db836228b1","slug":"managing-aiiras","fullItemName":"Managing AIIRAs"},{"id":"06c9d276-e5ea-5a0b-9ff4-343f10034763","slug":"managing-ace-inhibitors","fullItemName":"Managing ACE-inhibitors"},{"id":"df53e9a8-07f8-5d37-94cf-78e99d4c8216","slug":"managing-beta-blockers","fullItemName":"Managing beta-blockers"},{"id":"faad170c-d1ee-59ad-9847-f7afdda6d9b9","slug":"managing-diuretics","fullItemName":"Managing diuretics"},{"id":"a3ea6beb-7ee3-586c-9985-47c20d804195","slug":"covid-19","fullItemName":"COVID-19"}]},{"id":"7b9c5d56-39f1-53df-b1f9-2dcc5bbb498a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"df3b6e0c-ca5a-59eb-93e6-4b4370389ed2","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"7a756ff1-7152-5bdd-92ca-7f9e67351dd9","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f5e1707e-f2a9-54e0-92fa-71beb41e38af","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"691681cc-720f-5242-9fb3-3040860027e7","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"7f39ec24-cb87-5fba-ae6b-6fb2d9538859","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4afe2b30-f837-53a3-88df-7b1913a54081","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d4dace55-ef1c-5675-bdbe-180512d549fa","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e82d6013-cb43-59d5-9e2e-0af05276fb9d","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"7b34e2f0-171c-5c33-a274-c82b371b905e","slug":"key-drug-interactions","fullItemName":"Key drug interactions","depth":3,"htmlHeader":"<!-- begin field 4ead98e1-1bb2-4fde-a566-672818cd5d95 --><h3>Key drug interactions with ACE-inhibitors</h3><!-- end field 4ead98e1-1bb2-4fde-a566-672818cd5d95 -->","summary":"","htmlStringContent":"<!-- begin item a3743611-5f36-42b6-8ae9-4f7dd617daec --><!-- begin field 3c307b98-3b6e-4e1b-84b0-15757c7e91a5 --><p><strong>Important drug interactions of angiotensin-converting enzyme (ACE) inhibitors include:</strong></p><ul><li><strong>Alcohol</strong> — increased hypotensive effect of ACE-inhibitor.</li><li><strong>Aldosterone antagonists</strong> — careful monitoring is essential due risk of worsening renal function, hyperkalaemia, and hypotension.</li><li><strong>Aliskiren</strong> (a direct renin inhibitor) — combination therapy is not recommended. The combination of an ACE-inhibitor with aliskiren is contraindicated in people with diabetes mellitus or if the estimated glomerular filtration rate (eGFR) is less than 60 mL/minute/1.73 m<sup>2</sup>.</li><li><strong>Allopurinol</strong> — increased likelihood of haematological reactions.</li><li><strong>Alpha-blockers</strong> — increased risk of hypotension.</li><li><strong>Alprostadil</strong> — risk of hypotension.</li><li><strong>Angiotensin-II receptor antagonists</strong> — concomitant prescribing is not recommended (unless under specialist supervision).</li><li><strong>Antacids</strong> — concurrent administration may lead to reduced absorption — allow 2 hours between administration of each.</li><li><strong>Antibiotics</strong> — avoid concurrent use with tetracyclines. There is a risk of hyperkalaemia with trimethoprim.</li><li><strong>Antidiabetic agents</strong> — monitor glycaemic control closely during the first month of treatment due to increased blood glucose lowering effect with risk of hypoglycaemia. People with chronic kidney disease are particularly at risk. Increased risk of hypotension with sitagliptin.</li><li><strong>Antihypertensives</strong> — monitor blood pressure due to increased hypotensive effect.</li><li><strong>Antipsychotics</strong> — monitor blood pressure due to increased hypotensive effect.</li><li><strong>Baclofen</strong> — monitor blood pressure due to increased hypotensive effect.</li><li><strong>Ciclosporin</strong> — hyperkalaemia may occur during concomitant use of ACE inhibitors with ciclosporin. Monitoring of serum potassium is recommended. </li><li><strong>Diuretics</strong> — people already prescribed a diuretic may experience hypotension which may be profound. For people on 80 mg of furosemide or equivalent or above, consider discontinuing the diuretic for at least 24 hours prior to initiation of treatment or seeking specialist advice. For a person on a diuretic starting an ACE-inhibitor, the first dose of ACE-inhibitor can be taken at bedtime.</li><li><strong>Gold injections</strong> — symptoms of vasodilation including flushing, nausea, dizziness, and hypotension are more frequent.</li><li><strong>Heparin</strong> (including low-molecular weight heparin) — monitor potassium regularly (every 4 days) in particular in people at increased risk such as those with chronic kidney disease or diabetes mellitus.</li><li><strong>Immunosuppressant therapy</strong> — extreme caution is advised with periodic monitoring of white cell count.</li><li><strong>Levodopa</strong> — monitor blood pressure due to increased hypotensive effect.</li><li><strong>Lithium</strong> — concurrent treatment is not recommended but if considered essential careful monitoring of lithium levels is required.</li><li><strong>Mammalian target of rapamycin (mTor) inhibitor therapy </strong>(such as temsirolimus, sirolimus, everolimus ) — co-administration with ACE inhibitors may increase the risk of angioedema.</li><li><strong>Nitrates</strong> — monitor blood pressure due to increased hypotensive effect.</li><li><strong>Nonsteroidal anti-inflammatory drugs</strong> — concurrent treatment not recommended due to the risk of deterioration in renal function which can rarely cause acute kidney injury, particularly in the elderly, people who are dehydrated, or with chronic kidney disease (CKD).</li><li><strong>Potassium supplements/potassium salts</strong> — avoid or monitor serum potassium due to increased risk of hyperkalaemia. People with CKD or diabetes mellitus are particularly at risk of hyperkalaemia.</li><li><strong>Potassium-sparing diuretics</strong> — risk of hyperkalaemia particularly in the presence of other risk factors such as increased age, diabetes mellitus, doses of spironolactone greater than 25 mg daily and CKD. Close monitoring of potassium is needed and the presence of a loop diuretic may not prevent hyperkalaemia. It has been suggested that spironolactone should not be given with ACE-inhibitors in people with an eGFR under 30 mL/minute/1.73 m<sup>2</sup>.</li><li><strong>Sacubitril</strong> — manufacturer advises to avoid concomitant use of lisinopril with sacubitril/valsartan therapy. Lisinopril must not be initiated earlier than 36 hours after the last dose of sacubitril/valsartan.</li><li><strong>Sympathomimetics</strong> — reduced antihypertensive effect of ACE-inhibitor.</li><li><strong>Tricyclic antidepressants</strong> — monitor blood pressure due to increased hypotensive effect.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2014a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2014b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">MHRA, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">Preston, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">BNF 72, 2016</a>]</p><!-- end field 3c307b98-3b6e-4e1b-84b0-15757c7e91a5 --><!-- end item a3743611-5f36-42b6-8ae9-4f7dd617daec -->","subChapters":[]},{"id":"35f10d2d-9549-508e-967c-d7b3ea0f1d28","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 6d412950-04eb-4a13-bf61-a572bc6d1ad2 --><h3>ACE-inhibitors in pregnancy and breastfeeding</h3><!-- end field 6d412950-04eb-4a13-bf61-a572bc6d1ad2 -->","summary":"","htmlStringContent":"<!-- begin item e4900a7c-f6d7-42c8-a4c6-5002b1a219f4 --><!-- begin field a202d5f2-a58b-4230-a141-09eab48125de --><p><strong>Pregnancy</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">MHRA, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">UKTIS, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2014c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2014d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2014e</a>]</p><ul><li>Angiotensin-converting enzyme (ACE) inhibitors are not recommended during the first trimester of pregnancy. Evidence on the risk of teratogenicity in the first trimester of pregnancy is conflicting, and an increase in the risk of congenital malformation (particularly of the cardiovascular and central nervous system) cannot be excluded.</li><li>ACE-inhibitors are contraindicated during the second and third trimester as they are known to induce human fetal toxicity (decreased renal function, oligohydramnios, delay in skull ossification).</li></ul><p><strong>Breastfeeding</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">MHRA, 2009</a>]</p><ul><li>ACE-inhibitors are not recommended for use by women who are breastfeeding.<ul><li>During the first few weeks after delivery, ACE-inhibitors can cause profound neonatal hypotension; preterm babies may be at particular risk.</li><li>In women who are breastfeeding older infants, the use of captopril, enalapril, or quinapril may be considered if the use of an ACE-inhibitor is necessary. If used, the infant should be carefully followed up for possible signs of hypotension.</li></ul></li></ul><!-- end field a202d5f2-a58b-4230-a141-09eab48125de --><!-- end item e4900a7c-f6d7-42c8-a4c6-5002b1a219f4 -->","subChapters":[]},{"id":"00224eca-ce3d-59ab-af71-b74ccd6b9f52","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 3e3abc6d-dc17-47d1-bce4-3036e05eefa4 --><h3>Adverse effects of ACE-inhibitors</h3><!-- end field 3e3abc6d-dc17-47d1-bce4-3036e05eefa4 -->","summary":"","htmlStringContent":"<!-- begin item cc6574e5-5b6a-4b16-9af6-5dbc5f010885 --><!-- begin field 7362c982-815d-42ef-b48f-90db00a06562 --><ul><li><strong>Adverse effects of angiotensin-converting enzyme (ACE) inhibitors include:</strong><ul><li><strong>Hypotension</strong> which can be profound. It may cause dizziness, light headedness, and confusion.<ul><li>If hypotension is asymptomatic, there is no need to change treatment.</li><li>If hypotension is symptomatic but the person has no signs or symptoms of fluid overload, consider reducing the dose of any concomitant diuretic or seek specialist advice.</li></ul></li><li><strong>Deterioration in renal function</strong> — monitor renal function after starting an ACE-inhibitor, after each increase in dose, and every 3–6 months.<ul><li>Refer the person to a specialist if renal function is significantly reduced.</li></ul></li><li><strong>Hyperkalaemia</strong> — monitor serum electrolytes after starting an ACE-inhibitor, after each increase in dose, and every 3–6 months.</li><li><strong>Cough</strong> — if the cough is intolerable (for example it prevents the person from sleeping) and other causes have been ruled out, consider switching to an <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/prescribing-information/managing-aiiras/\">angiotensin-II receptor antagonist</a>.</li><li><strong>Angio-oedema</strong> — higher incidence reported in Afro-Caribbean people. Angio-oedema may be of delayed onset.</li><li><strong>Rash</strong> (may be associated with pruritus and urticaria).</li><li><strong>Gastrointestinal symptoms</strong> including taste disturbances, nausea, vomiting, dyspepsia, diarrhoea, constipation, and abdominal pain.</li><li><strong>Pancreatitis</strong>, altered liver function tests, cholestatic jaundice, hepatitis, fulminant hepatic necrosis, hepatic failure — discontinue if marked elevation of hepatic enzymes or jaundice.</li><li><strong>Respiratory tract symptoms</strong> including sinusitis, rhinitis, bronchospasm, and sore throat.</li><li><strong>Hypoglycaemia.</strong></li><li><strong>Blood disorders</strong> including thrombocytopenia, leucopenia, neutropaenia, haemolytic anaemia, raised erythrocyte sedimentation rate, eosinophilia, and leucocytosis.</li><li><strong>Other adverse effects</strong> including headache, fatigue, malaise, paraesthaesia, proteinuria, fever, vasculitis, myalgia, arthralgia, positive nuclear antibody, and photosensitivity.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">McMurray et al, 2005</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">National Clinical Guideline Centre for Acute and Chronic Conditions, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">BNF 72, 2016</a>]</p><!-- end field 7362c982-815d-42ef-b48f-90db00a06562 --><!-- end item cc6574e5-5b6a-4b16-9af6-5dbc5f010885 -->","subChapters":[]},{"id":"e20f5ee4-e4c2-5951-9baf-1c911f72f397","slug":"dose-titration-monitoring","fullItemName":"Dose, titration, and monitoring","depth":3,"htmlHeader":"<!-- begin field b2feba7f-4c67-49de-a001-814896a2ace6 --><h3>Dose, titration, and monitoring of ACE-inhibitors</h3><!-- end field b2feba7f-4c67-49de-a001-814896a2ace6 -->","summary":"","htmlStringContent":"<!-- begin item 393180b5-0fc3-404f-b274-8cdc856558db --><!-- begin field 09016e90-b881-4271-a459-82cf8090bd51 --><ul><li><strong>Seek specialist advice before starting treatment with an ACE-inhibitor if the person is using high doses of a loop diuretic</strong> (equivalent to 80 mg furosemide daily or more).</li><li><strong>Measure renal function, serum electrolytes and blood pressure before prescribing an ACE-inhibitor and start with a low dose (starting doses are given in Table 3).</strong><ul><li>If the person has chronic kidney disease (CKD) and a serum potassium greater than 5 mmol/L do not start treatment with an ACE inhibitor.</li><li>Advise the person to be aware of the possibility of first-dose hypotension, particularly if a diuretic is concurrently prescribed. For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/prescribing-information/managing-ace-inhibitors/#key-drug-interactions\">Drug interactions</a>.</li></ul></li><li><strong>Recheck renal function, serum electrolytes, and blood pressure 1-2 weeks after starting treatment.</strong><ul><li>Earlier monitoring (after 5–7 days) may be required for people:<ul><li>With existing CKD stage 3 or higher.</li><li>Aged 60 years or over.</li><li>With relevant comorbidities such as diabetes mellitus or peripheral arterial disease.</li><li>Taking a combination of an ACE-inhibitor plus a diuretic or an aldosterone antagonist.</li></ul></li><li>Some increase in serum creatinine and potassium levels is expected after starting or increasing the dose of an ACE-inhibitor. For interpretation of monitoring, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/prescribing-information/managing-ace-inhibitors/#managing-abnormal-results\">Managing abnormal results</a>.</li></ul></li><li><strong>Titrate the dose upwards at short intervals</strong> (for example every 2 weeks) until the target dose or the highest tolerated dose is reached (target doses are given in Table 3).<ul><li>After each upward titration, monitor the person's renal function and blood pressure. Do not increase the dose further if there is worsening renal function or hyperkalaemia.</li><li>For interpretation of monitoring, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/prescribing-information/managing-ace-inhibitors/#managing-abnormal-results\">Managing abnormal results</a>.</li></ul></li><li><strong>Maintain the ACE-inhibitor at the target dose (or highest tolerated dose) indefinitely unless adverse effects occur.</strong></li><li><strong>Once treatment is stable, measure renal function and serum electrolytes at least every monthly for 3 months and then at least every six months and at any time if the person becomes acutely unwell. </strong><ul><li>More frequent monitoring may be required if clincially appropriate, when there are concerns regarding the person's clinical condition, concomitant drugs, or comorbidities.</li></ul></li><li><strong>Advise the person that if they develop diarrhoea and vomiting while taking an ACE-inhibitor,</strong> they should maintain their fluid intake and stop the ACE-inhibitor for 1–2 days until they recover.<ul><li>Stopping treatment for a short time is thought to avoid dehydration, hypotension and acute renal failure, and should not cause a sudden deterioration in heart failure.</li><li>If symptoms persist beyond 2 days they should see a GP and have their renal function checked.</li><li>For further information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/management/information-advice-follow-up-referral/#information-advice\">Self-care advice</a>.</li></ul></li></ul><p><strong>Table 3.</strong> Doses of ACE-inhibitors recommended for heart failure.</p><table data-table-id=\"ffe7ffe9-3355-4dff-8c6b-acce014f4ade\"><thead><tr><th colspan=\"1\" scope=\"col\">ACE inhibitor</th><th colspan=\"1\" scope=\"col\">Initial dose</th><th colspan=\"1\" scope=\"col\">Target dose*</th></tr></thead><tbody><tr><td colspan=\"1\">Captopril</td><td colspan=\"1\">6.25 mg to 12.5 mg, two or three times a day</td><td colspan=\"1\">50 mg three times a day</td></tr><tr><td colspan=\"1\">Enalapril</td><td colspan=\"1\">2.5 mg twice a day</td><td colspan=\"1\">10 mg to 20 mg, twice a day</td></tr><tr><td colspan=\"1\">Fosinopril</td><td colspan=\"1\">10 mg once a day</td><td colspan=\"1\">40 mg once a day</td></tr><tr><td colspan=\"1\">Lisinopril†</td><td colspan=\"1\">2.5 mg once a day</td><td colspan=\"1\">20 mg to 35 mg, once a day</td></tr><tr><td colspan=\"1\">Perindopril erbumine</td><td colspan=\"1\">2 mg once a day</td><td colspan=\"1\">4 mg once a day</td></tr><tr><td colspan=\"1\">Quinapril</td><td colspan=\"1\">2.5 mg once a day</td><td colspan=\"1\">10 mg to 20 mg daily in 1 to 2 divided doses, maximum 40 mg daily</td></tr><tr><td colspan=\"1\">Ramipril</td><td colspan=\"1\">2.5 mg once a day</td><td colspan=\"1\">5 mg twice a day or 10 mg once a day ‡</td></tr><tr><td colspan=\"3\">* Use the higher dose if there are still symptoms at the lower target dose. † Do not increase lisinopril by increments of more than 10 mg at intervals of at least 2 weeks. ‡ Ramipril maximum dose is recommended to be given in 2 divided doses</td></tr><tr><td colspan=\"3\"><p><strong>Data from:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">SIGN, 2016</a>]</p><p><strong>Note:</strong> The BNF recommends starting on lower doses of ramipril (1.25 mg once a day) and enalapril (2.5 mg once a day) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">BNF 72, 2016</a>].</p></td></tr></tbody></table><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">Smellie et al, 2007a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">Smellie et al, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">NICE, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">National Clinical Guideline Centre for Acute and Chronic Conditions, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">McKelvie et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">National Clinical Guidelines Centre, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">BNF 72, 2016</a>]</p><!-- end field 09016e90-b881-4271-a459-82cf8090bd51 --><!-- end item 393180b5-0fc3-404f-b274-8cdc856558db -->","subChapters":[]},{"id":"3c6757fb-404d-5701-b9e9-533c82caeaf4","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 1fc53762-4b8a-4ae3-985b-3e7b36b65ca6 --><h3>Contraindications and cautions of ACE-inhibitors</h3><!-- end field 1fc53762-4b8a-4ae3-985b-3e7b36b65ca6 -->","summary":"","htmlStringContent":"<!-- begin item 50859eff-24ff-49c0-b17e-bfefbfacb721 --><!-- begin field 0c1d0d74-06e2-4523-8f48-bdc27b284eec --><ul><li><strong>Do not prescribe angiotensin-converting enzyme (ACE) inhibitors to people with:</strong><ul><li>Hereditary or idiopathic angio-oedema, or a history of angio-oedema associated with previous exposure to ACE-inhibitors.</li><li>Bilateral renal artery stenosis or renal artery stenosis in a single functioning kidney as ACE-inhibitors reduce or abolish glomerular filtration and are likely to cause severe and progressive renal failure.</li><li>Some ACE-inhibitors contain lactulose and should not be used by people with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption.</li><li>Chronic kidney disease (CKD) with a pre-treatment serum potassium concentration of greater than 5.0 mmol/L.</li></ul></li><li><strong>Use ACE-inhibitors with caution in people with:</strong><ul><li>Concurrently prescribed diuretics (especially more than 80 mg of furosemide daily or its equivalent). First doses can cause hypotension (especially in those taking high doses, on a low-sodium diet, on dialysis, or with dehydration). For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/prescribing-information/managing-ace-inhibitors/#key-drug-interactions\">drug interactions</a>.</li><li>Peripheral arterial disease or generalized atherosclerosis as there is a risk of clinically silent renovascular disease.</li><li>Pre-existing renovascular disease (specialist initiation only).</li><li>Chronic kidney disease — monitor the response (hyperkalaemia is more common) and consider dose adjustment.</li><li>Collagen vascular disease (such as rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis and polyarteritis nodosa) — increased risk of agranulocytosis.</li><li>Severe or symptomatic aortic stenosis (risk of hypotension).</li><li>Mitral valve stenosis.</li><li>Hypertrophic cardiomyopathy.</li><li>Unstable heart failure.</li><li>Hypovolaemia or hypotension (systolic pressure below 90 mmHg) or concurrent high-dose vasodilator therapy.</li><li>Hyponatraemia (plasma sodium concentration below 130 mmol/L).</li><li>High pre-treatment serum potassium level (greater than 5 mmol/L).</li><li>Impaired liver function — close monitoring is required.</li></ul></li><li><strong>Consider the possibility of <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/prescribing-information/managing-ace-inhibitors/#key-drug-interactions\">drug interactions</a> with other medications.</strong></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2014a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2014b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">MHRA, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">National Clinical Guidelines Centre, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">BNF 72, 2016</a>]</p><!-- end field 0c1d0d74-06e2-4523-8f48-bdc27b284eec --><!-- end item 50859eff-24ff-49c0-b17e-bfefbfacb721 -->","subChapters":[]},{"id":"db3cdefb-1011-55e6-a900-1b0ad19ca0ba","slug":"managing-abnormal-results","fullItemName":"Managing abnormal results","depth":3,"htmlHeader":"<!-- begin field 84c4bc01-cefc-4e42-b0a0-b15a6a4bf202 --><h3>Managing abnormal results with ACE-inhibitors</h3><!-- end field 84c4bc01-cefc-4e42-b0a0-b15a6a4bf202 -->","summary":"","htmlStringContent":"<!-- begin item 52b02449-3450-4225-a1e8-dedb26cb3369 --><!-- begin field 49c4a1b7-ff7c-4a89-b90a-8ce741f5b0ff --><p>Some increase in creatinine and potassium levels is expected after starting or increasing the dose of an angiotensin-converting enzyme (ACE) inhibitor.</p><ul><li><strong>Managing creatinine and estimated glomerular filtration rate (eGFR)</strong><ul><li>If the serum creatinine level increases by more than 20% or the eGFR falls more than 15%, re-measure renal function within 2 weeks.</li><li>An increase of the serum creatinine level of less than 30% does not require further action.</li><li>An increase of the serum creatinine level of 30–50% (or to over 200micromol/L) or eGFR less than 30 mL/min/1.73 m<sup>2</sup> should prompt clinical review of volume status and temporary dose reduction, or withdrawal of the diuretic or ACE-inhibitor.</li><li>An increase of the serum creatinine level of more than 50% or to a level greater than 256 micromol/L (eGFR approximately 20-25 mL/min/1.73 m<sup>2</sup>) should prompt dose reduction or withdrawal of diuretic and/or stopping the ACE-inhibitor and consideration of specialist referral.</li><li>An increase in the serum creatinine level of more than 100% or to greater than 310 micromol/L or eGFR less than 20 mL/min/1.73 m<sup>2</sup>, stop the ACE-inhibitor and seek specialist advice.</li><li>If the eGFR decreases by 25% or more, or the serum creatinine level increases by 30% or more investigate other causes of deteriorating renal function, such as volume depletion. Stop or reduce the dose of the following drugs (where appropriate) if the person is taking them:<ul><li>Nephrotoxic drugs (such as non-steroidal anti-inflammatory drugs).</li><li>Vasodilators (such as calcium-channel blockers, nitrates).</li><li>Potassium supplements or potassium-sparing diuretics.</li><li>Diuretics (consider dose reduction if the person is hypovolaemic).</li></ul></li><li>If the decrease in eGFR or the increase in serum creatinine level persists despite these measures:<ul><li>Stop the ACE-inhibitor, or reduce the dose to a previously tolerated dose and recheck levels in 5–7 days.</li></ul></li><li>If there is a significant decline in the eGFR consider the possibility of renal artery stenosis and refer for specialist assessment.</li></ul></li><li><strong>Managing serum potassium level</strong><ul><li>A rise of serum potassium level to up to 5.5 mmol/L is acceptable.</li><li>If elevated potassium levels persist, review concurrent medication that may increase potassium (including spironolactone, nonsteroidal anti-inflammatory drugs, and nephrotoxic drugs).</li><li>A rise of serum potassium to 5.5–6.0 mmol/L should prompt stopping the ACE-inhibitor and seeking specialist advice.</li><li>A rise of serum potassium to over 6.0 mmol/L should prompt stopping of all medications that may increase potassium (including the ACE-inhibitor) and seek urgent specialist advice.</li></ul></li><li><strong>Managing serum sodium level</strong><ul><li>Seek specialist advice if serum sodium falls to under 132 mmol/L.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">Smellie et al, 2007a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">Smellie et al, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">London and South East Medicines Information Service et al, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2012</a>]</p><!-- end field 49c4a1b7-ff7c-4a89-b90a-8ce741f5b0ff --><!-- end item 52b02449-3450-4225-a1e8-dedb26cb3369 -->","subChapters":[]},{"id":"9638a486-f0f3-54c7-b483-d6137edc7134","slug":"choice-of-ace-inhibitor","fullItemName":"Choice of ACE-inhibitor","depth":3,"htmlHeader":"<!-- begin field cf365db9-b40e-4299-aede-f4573e024bfa --><h3>Choice of ACE-inhibitor</h3><!-- end field cf365db9-b40e-4299-aede-f4573e024bfa -->","summary":"","htmlStringContent":"<!-- begin item 901c960a-a91c-4e4a-b404-fd4343d9cb06 --><!-- begin field ef4641de-cded-4e8a-b2f6-a31ef7a2d7dd --><ul><li class=\"GListbullet1\">The angiotensin-converting enzyme (ACE) inhibitors licensed in the UK for the treatment of heart failure are captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, and ramipril.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">BNF 72, 2016</a>]</p><!-- end field ef4641de-cded-4e8a-b2f6-a31ef7a2d7dd --><!-- end item 901c960a-a91c-4e4a-b404-fd4343d9cb06 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}